Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-07
1998-08-11
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 3, 514 4, 514 21, 514250, 514288, 514908, A61K 3800
Patent
active
057927480
ABSTRACT:
This invention relates to a method for inhibiting the growth of neoplasms, in a mammal having a prolactin profile. This method involves comparing the prolactin profile of the afflicted mammal to a standard prolactin profile for healthy mammals of the same species and sex and adjusting the prolactin profile of the afflicted mammal to conform to or approach the standard prolactin profile for a mammal of the same species and sex of the afflicted mammal, thereby inhibiting the neoplastic growth.
REFERENCES:
patent: 5344832 (1994-09-01), Cincotta et al.
patent: 5468755 (1995-11-01), Cincotta et al.
C. Bartsch et al., Ann. NY Acad. Sci., 719:502-525, 1994.
A.M. Leone et al., J. Pineal Res., 17:17-19, 1994.
C. Bartsch et al., J. Neural Transmission, 52:269-279 (1981).
J. Redman et al., Science, 219:1089-1091 (1983).
F. Wauldhaser et al. (1984) Melatonin in Human Body Fluids: Clinical Significance. In The Pineal Gland ed. Russel J. Reiter pp. 345-363.
W. Regelson et al. (1987) Melatonin: A Rediscovered Antitumor Hormone?0 Cancer Investigation 5(4):379-385.
B. Neri et al. (1994) Modulation of Human Lymphoblastoid Interferon Activity by Melatonin in Metastatic Renal Carcinoma. Cancer 73:3015-3019.
P. Lissoni et al. (1992) Randomized Study with the Pineal Hormone Melatonin versus Supportive Care Alone in Advanced Nonsmall Cell Lung Cancer Resistant to a First-Line Chemotherapy Containing Cisplatin. Oncology 49:336-339.
R. Aldeghi et al. (1994) Low-dose Interleukin-2 Subcutaneous Immunotherapy in Association with the Pineal Hormone Melatonin as a First-Line Therapy in Locally Advanced or Metastatic Hepatocellular Carcinoma. Eur. J. Cancer 30A(2):167-170.
P. Lissoni et al. (1994) A Randomized Study with the Pineal Hormone Melatonin versus Supportive Care Alone in Patients with Brain Metastases Due to Solid Neoplasms. Cancer 73:699-701.
P. Lissoni et al. (1994) Efficacy of the Concomitant Administration of the Pineal Hormone Melatonin in Cancer Immunotherapy with Low-Dose IL-2 in Patients with Advanced Solid Tumors Who Had Progressed on IL-2 Alone. Oncology 51:344-347.
P. Lissoni et al. (1995) Immunoendocrine Therapy with Low-Dose Subcutaneous Interleukin-2 Plus Melatonin of Locally Advanced or Metastatic Endocrine Tumors. Oncology 52:163-166.
S. Barni et al. (1995) A Randomized Study of Low-Dose Subcutaneous Interleukin-2 Plus Melatonin versus Supportive Care Alone in Metastatic Colorectal Cancer Patients Progressing under 5-Fluorouracil and Folates. Oncology 52:243-245.
P. Lissoni et al. (1995) Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. British J. of Cancer 71(4):854-856.
Lissoni, P. et al., (1990), A study of pineal-prolactin interaction: prolactin response to an acute melatonin injection in patients with hyperprolactinemia, Medline Abstract, Identifier No.: 90229655.
Lissoni, P. et al., (1989), Endocrine and immune effects of melatonin therapy in metastatic cancer patients, Medline Abstract, Identifier No.: 89289750.
Kikuchi, Y. et al., (1989), Inhibition of human ovarian cancer cell proliferation in vitro by neuroendocrine hormones, Medline Abstract, Identifier No.: 89079088.
Chatterjee, S. et al., (1989), Effects of melatonin on the growth of MtT/F4 anterior pituitary tumor: evidence for inhibition of tumor growth dependent upon the time of administration, Medline Abstract, Identifier No.: 90095797.
Di Stefano, A. et al., (1994), Inhibitory effect of melatonin on production of IFN gamma or TNF alpha in peripheral blood mononuclear cells of some blood donors, Medline Abstract, Identifier No.: 95239580.
Crespo, D. et al., (1994), Interaction between melatonin and estradiol on morphological and morphometric features of MCF-7 human breast cancer cells, Medline Abstract, Identifier No.: 95106114.
Cos, S. et al., (1994), Differences between pulsatile or continuous exposure to melatonin on MCF-7 human breast cancer cell proliferation, Medline Abstract, Identifier No.: 95007479.
Maestroni, G. et al., (1994), Colony-stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin 4, Medline Abstract, Identifier No.: 94340606.
Kane, M. et al., (1994), Serum melatonin levels in melanoma patients after repeated oral administration, Medline Abstract, Identifier No.: 94305357.
Furuya, Y. et al., (1994), 5-Fluorouracil attenuates an oncostatic effect of melatonin on estrogen-sensitive human breast cancer cells (MCF7), Medline Abstact, Identifier No.: 94291081.
Lissoni, P. et al., (1993), Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status, Medline Abstract, Identifier No.: 94225687.
Barnett, A.H. et al., (1980) Effect of bromocriptine on maturity onset diabetes. Postgrad. Med. J. 56:11-14.
Meier, A.H. et al., (1992) Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia 48:248-253.
Cincotta Anthony H.
Meier Albert H.
Raymond Richard L.
The Board of Supervisors of Louisiana State University and Agric
The General Hospital Corporation
LandOfFree
Method for inhibiting neoplastic disease in mammals does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting neoplastic disease in mammals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting neoplastic disease in mammals will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-389037